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                                                        Abstract 
We summarise findings on 643 renal biopsies on Indigenous people across Australia, and 
compare them with 249 non-Indigenous biopsies. The relative population-adjusted biopsy 
frequencies were 16.9, 6.6 and 1 respectively, for Aboriginal people living remotely or very 
remotely (R/VR), for Torres Strait Islander people, and for non-remote-living Aboriginal 
people. Indigenous people more often had heavy proteinuria and renal failure at biopsy. No 
single condition defined the Indigenous biopsies, and where biopsy rates were high, all 
common conditions were in absolute excess.  Indigenous people were more often diabetic 
than non-Indigenous people, but diabetic changes were still present in fewer than half their 
biopsies. They also had higher rates of segmental sclerosis, post-infectious 
glomerulonephritis, and mixed morphology. Among the great excess of biopsies in R/VR 
Aborigines, females predominated, with younger age at biopsy and larger MGVs.    
Glomerulomegaly characterized biopsies with mesangiopathic changes only, with IgA 
deposition or with diabetic change, and with focal glomerulosclerosis (FSGS).  This series 
reveals great variations in biopsy rates and findings in Indigenous Australians. It refutes 
prevailing dogma that most indigenous renal disease is due to diabetes. Glomerulomegaly in 
R/VR Aboriginal people probably results from nephron deficiency related to low birth weight, 
contributes to accentuated susceptibility to kidney disease, and predisposes to 
FSGS.glomerulosclerosis (FSGS).  This series reveals great variations in biopsy rates and 
findings among Indigenous Australians. It refutes prevailing dogma that most indigenous renal 
disease is due to diabetes. Glomerulomegaly in R/VR Aboriginal people probably results from 
nephron deficiency, in part related to low birth weight, contributes to the accentuated 
susceptibility to kidney disease, and predisposes to FSGS.   
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Introduction 
It is well known that Australia’s Indigenous people are experiencing an epidemic of 
hypertension, type 2 diabetes, cardiovascular disease, renal disease and renal failure (1,2).  
Renal disease has especially captured attention because of the high costs of treating subjects 
with renal replacement therapy (RRT). It is less well known that disease burden and outcomes 
differ markedly among Indigenous people across the country (3-9).  
 
Figure 1 is a map of Australia by five categories of “remoteness” as defined by the 
Accessibility/Remoteness Index of Australia (ARIA)+ methodology (10). Most of the interior of 
the continent and the north and west are remote or very remote, as are the Torres Strait 
Islands. Today only about 25% of Indigenous people live in remote or very remote (R/VR) 
areas, while most live in urban or semiurban environments. Although the Torres Strait Islands 
are characterized as very remote, many Torres Strait Islander (TSI) people now live around 
population centers. Figure 1 also marks out Australia’s states and territories, which were 
constituted without consideration of distribution of Indigenous people, but now bear most of 
the responsibility for, and costs of, RRT for their constituent populations. 
Table 1 shows the distribution of the 2006 Indigenous population by categories of remoteness 
of their usual place of residence, and by state/territory (11).  New South Wales (NSW) has the 
largest Indigenous population, but most do not live remotely; Queensland has the next largest 
Indigenous population but only 19% live R/VR and almost all the Aboriginal people in Victoria 
and Tasmania live near population centres.  However, >80% of Aboriginal people in the 
Northern Territory (NT) and about 42% in Western Australia (WA) live in R/VR areas.    
 
Assignment of Indigenous status for Australia’s census is through self report, and it embraces 
very heterogeneous populations. Aboriginal people and TSI are distinct groups, of 
Micronesian and Melanesian descent respectively, with different cultures, lifestyles, diets, 
body habitus and health status.  Moreover, mainland Aboriginal Australians are themselves 
very heterogeneous in location, languages, non-Indigenous admixture, lifestyle, 
socioeconomic status, body habitus, health, life expectancy, and access to, and utilization of, 
services. All documented health parameters, including birth weights, hospitalization rates, and 
perinatal, infant and adult mortality, are worse in those living in R/VR areas than in those living 
less remotely.  
 
Cass et al. described vast variation by region and remoteness in the incidence of Indigenous 
people beginning renal replacement therapy (RRT) from 1993-1998 (12,13) (Figure 2), and 
confirmed it again, 10 years later (14). There was a great, though variable, excess in RRT 
incidence in Indigenous people in remote and very remote areas, and much lower rates for 
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those living closer to population centers. The gradient in RRT correlated strongly and directly 
with level of socioeconomic disadvantage, of which low birth weight is one indicator (13). 
Variation by remoteness has more recently been reported by the Australian Institute of Health 
and Welfare, from ANZDATA information (15); that report also defined an excess of females 
among incident R/VR Indigenous people, in contrast with the male excess among non-
Indigenous RRT patients (1,15,16).   
 
Figure 3 shows the very different RRT incidence rates by state/territory, ranging from less 
than twice that of non-Indigenous Australians (about 110 pm per year) to a 14-fold increase 
(2). These differential rates, which are directly linked to RRT treatment costs on a population 
basis, largely reflect the different proportions of Indigenous populations by remoteness of 
residence, as noted in Table 1.  
 
Awareness of the excess of kidney disease in Aboriginal people was first heightened in the 
Top End of the NT and in Central Australia, and renal biopsies were frequently performed to 
define the processes (17,18).  A high frequency of subjectively assessed glomerulomegaly 
was described, along with mesangial proliferation and focal sclerosis (17,18).  
Glomerulomegaly was later confirmed by formal measurements, and again shown to 
associate with focal segmental glomerulosclerosis (FSGS) (19,20).  However, the definition of 
some of the morphologic features and their relationships to possible “diagnoses” have been 
uncertain, and practitioners in other jurisdictions have questioned the applicability of these 
findings to the Indigenous populations they serve.    
 
We therefore organized a review of all Indigenous renal biopsies across Australia. Its 
objectives were to reach consensus on pathological findings and terminology, quantify 
glomerular size, and establish and compare regional biopsy profiles. 
 
Results 
 
Among 1026 biopsies retrieved and reviewed; 735 were from indigenous people.  Of these, 
38 were of transplanted kidneys, 20 were second or subsequent biopsies of kidneys in the 
same person and 24 contained no glomeruli or were otherwise non-evaluable. The final 
Indigenous series consisted of 653 eligible biopsies, whose light microscopic (LM) findings 
were evaluated by our expert panel of nephropathologists, (Table 2 and Methods). 
Photographs or reports of immunofluorescent (IF) examinations were available for 577 and 
497 had electron microscopy (EM) studies.   
 
Ten biopsies 10 from Pacific Islanders and 10 of unknown ethnicity, were excluded. There 
were 249 evaluable non-transplant biopsies on non-Indigenous people, described here; 224 
had reports of IF, and 240 had EM photographs and/or reports.  
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Table 3 shows the number of evaluable biopsies in Indigenous people by state/territory, by 
categories of remoteness and by Aboriginal, TSI or TSI/Aboriginal designation. 
Remoteness classification was lacking for 33. Most biopsies were from the NT (Top End 
and Central Australia) and Queensland, which included all TSI people, with more modest 
numbers from WA and South Australia, only five for from NSW and none from the 
Australian Capital Territory. Two Indigenous biopsies were identified in Victoria in 2011, but 
time did not permit ethics approvals needed for their inclusion in this review. Most 
Aboriginal biopsies were from people living in R/VR areas, and only 22 were from 
Aboriginal people living in or near major cities. There were 73 biopsies from TSI people and 
12 from people of mixed TSI/Aboriginal descent.  
 
Indigenous biopsy findings were analysed in three groups, Aboriginal R/VR, Aboriginal non-
remote (from major cities- MC, inner regional areas- IR, outer regional areas-OR) and as TSI. 
All were compared with findings in the non-Indigenous biopsies. Data from 11 people of mixed 
TSI/Aboriginal descent, who had remoteness classification, were included in analyses of both 
the Aboriginal and TSI groups, which did not substantially change the group results.    
 
Figure 4A shows estimates of the population-based frequencies of biopsies by these 
categories, using the total number of biopsies as the numerator and the regional 2006 census 
populations as denominators. This is not an annual estimate because biopsies were gathered 
from 1982 to 2005, and the Indigenous population has more than doubled over that interval. 
Nonetheless, with the same assumptions applied to each group, the relative ranking is 
informative.  The figure demonstrates, on an exponential scale, the great excess of biopsies in 
people from R/VR areas, and a predominance of females in that group, while Aboriginal 
people closer to population centers had much lower rates and no female excess.  Relative to 
the population-adjusted frequency of biopsies in non-remote Aboriginal people, there was a 
6.6-fold greater biopsy frequency in TSI people and a 16.9-fold increase in biopsies from 
R/VR Aboriginal people. This ranking has similar ranking to that of RRT incidence rates 
(Figure 4B).  Rates of overt albuminuria ascertained from limited localized studies in each 
region (21-24), have similar rankings (Figure 4C).   
 
Table 4 shows some demographic and clinical features of biopsy subjects.  An excess of 
females among biopsied R/VR Aboriginal people was confirmed, and was also seen in TSI 
people. This contrasts with a male excess in less remote-living Aboriginal people, like that in 
non-Indigenous people. Median age at biopsy was lowest in R/VR Aboriginal people, and in 
TSI and non-remote Aboriginal people was more like those of non-Indigenous people. 
Indigenous people were more frequently identified as diabetic at time of biopsy. They more 
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often had nephrotic range proteinuria, renal insufficiency and renal failure at biopsy than non-
Indigenous people.   
 
Table 4 also shows some of the LM morphologic biopsy features.  The median number of 
glomerular profiles per biopsy was about 14.  The measured average glomerular tuft volume 
in non-endstage kidneys was significantly larger in R/VR Aboriginal people than in the other 
three groups. The values were unchanged when restricted to biopsies with >4 glomerular 
profiles (95% of non-Indigenous and 91% of Indigenous biopsies) (25). Almost all Indigenous 
biopsies had mesangiopathic change (Table2, including items #2,#3) and more often had 
segmental glomerular tuft sclerosis (items #12-18)  than non-Indigenous biopsies.  Most 
biopsies had interstitial inflammation and fibrosis with tubular atrophy and loss (items 
#23,#24,#28,#29). Crescents, largely cellular and fibrocellular, were present in substantial 
proportions of biopsies, and involved more than 10% of glomeruli (item #9).  Most had 
vascular changes (items #31-35).  Indigenous people more often had end-stage kidneys at 
biopsy.   
  
The table also shows the final assessments, derived from the experts reviewers’ “diagnoses” 
and the final collation of individual morphologic variables.  Leading assessments among R/VR 
Aboriginal biopsies were diabetic change, mesangiopathic glomerulonephritis (GN) (without 
IgA) and IgA nephropathy.  Indigenous biopsies more often had diabetic changes, with the 
highest proportions in non-remote living Aborigines and TSI. Nonetheless, diabetic change 
was found in fewer than half the Indigenous biopsies. The proportion of biopsies with a 
diagnosis of FSGS was highest in biopsies from R/VR Aboriginal people.  IgA nephropathy 
was well represented in all the indigenous groups, although in lower absolute proportions for 
R/VR Aboriginal people, among whom 14% had crescents.  Substantial numbers of 
Indigenous people had diffuse proliferative GN (40 to 60% with crescents), which included 
much higher proportions with post-infectious GN.  The constitution of the infiltrates associated 
with interstitial nephritis was similar in all groups: with lymphocytic/histiocytic cells always 
present, while about 50% also had plasma cells, and about 30% had 
eosinophils/polymorphonuclear cells.  Sixteen Indigenous people, all from R/VR areas had 
amyloid in their kidney biopsies, which, when (infrequently) specified, was the AL type. The 
proportions with membranous GN were lower in the R/VR Aboriginal series and the TSI 
biopsies than in non-Indigenous biopsies. Indigenous people had higher proportions of 
biopsies with multiple “diagnoses”, (excluding cases of secondary FSGS with a specified 
underlying condition), of which most fell into four major categories—diabetic nephropathy plus 
post-infectious GN (n=21), diabetic nephropathy plus IgA nephropathy (n=13), diabetic 
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nephropathy plus interstitial nephritis (n=10) and diabetic nephropathy plus diffuse proliferative 
GN (n=6).   
 
Figure 5 demonstrates the higher mean glomerular volumes in biopsies of R/VR Aboriginal 
people compared with the other study groups.  Figure 6 shows that, among groups mutually 
exclusive groups of ‘diagnoses” in non-endstage kidneys in R/VR Aboriginal people, average 
mean glomerular volumes in decreasing rank order, were mesangiopathic changes alone, 
FSGS, with similar values for secondary and primary forms (means 4.1, CI 3.5-4.7 vs 3.8, CI 
3.1-4.5 ) and diabetic nephropathy.  The average value was also elevated in people with IgA 
nepropathy without FSGS, but the numbers were smaller.  
 
Table 5 shows that, with retrospective application of the 2010 classification of Thijs et al (26), 
the major classes of diabetic nephropathy in all subjects groups were severe mesangial 
expansion (Class IIB) and advanced diabetic sclerosis (Class IV), with substantial proportions 
with diabetic nodular sclerosis.  
 
Table 6 shows classifications of FSGS (27). Cases of secondary FSGS, further defined in the 
legend of the table, outnumbered apparent primary FSGS in Indigenous people. The major 
histologic category in both primary and secondary forms was the unspecified type, followed by 
the perihilar variant.   
 
Applying the proportions of diagnoses/assessment to the relative frequencies of biopsies on a 
population basis, there was a great excess of most leading biopsy findings among R/VR 
Aborigines, and a considerable excess in TSI people, as shown in Figure 7.    
 
Discussion 
 
This is the first nationwide perspective on renal biopsies in Australian Indigenous people. It 
shows marked heterogeneity of biopsy rates amongst them, and similarities as well as 
differences in morphologic findings.  Among R/VR Aboriginal people, there was a striking 
relative and absolute excess of biopsies, a female predominance, a younger age at biopsy 
and larger glomeruli compared with other Indigenous as well as non-Indigenous biopsies. 
There was a relative excess of biopsies in TSI people, a female predominance, but with an 
older age at biopsy. Among the many fewer non-remote Aboriginal people with biopsies, there 
was no female excess and their ages at biopsy were higher, both more aligned to the non-
Indigenous biopsy series.   
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The biopsy frequencies and gender distributions among the Indigenous groups approximately 
parallel their RRT rates and patterns. They are also compatible with community-based 
distribution of overt albuminuria found in a very limited number of localized studies in the 
relevant groupings, all of which contrast with 0.6% prevalence in adult non-Indigenous 
Australians, without a female dominance (28). Thus there are reassuring synergies between 
community-based disease frequency, biopsy rates and terminal renal failure.   
 
The absolute numbers and the population-based rates of biopsies in the states and territories 
reflect to a large extent the characteristics of their Indigenous populations and the variations of 
the distributions of their Aboriginal people by remoteness. This helps explain the different 
impressions of nephrologists in the various states/territories about the frequency and nature of 
renal disease they see in Indigenous people.    
 
All the usual changes and “diagnoses” were represented in Indigenous people in this 
biopsy series. Notable in all three Indigenous groups were the high, though variable, 
proportions of diabetics, more advanced renal disease at biopsy, their higher frequency of 
diabetic nephropathic changes, of segmental glomerular tuft injury, and of post-infectious 
GN.  Proportions of biopsies with IgA nephropathy, other forms of mesangiopathic GN and 
membranous GN were not higher in R/VR Aboriginal and TSI biopsies than in non-
Indigenous people. However, as we have emphasized (Figure 7), wherever the renal 
disease burden and the biopsy rates are high, the absolute number of biopsies with any 
finding of substantial frequency represents a population-based excess.   
 
We cannot comment on genetic determinants of renal disease among Indigenous people, 
although genomic studies have begun. However, the major drivers of excess renal disease 
are potentially modifiable risk factors, such as intrauterine growth retardation and low birth 
weight, poor nutrition in infancy, childhood and adult life, high levels of adult body mass index 
(BMI) and diabetes, and the burden of infections and inflammation (29-31).   These are 
generally worse in Aborigines from R/VR areas: for example, the frequency of low birth weight 
is still increased 2-3-fold (32), and, in the NT, was present in about one third of births 40 years 
ago (30,31,33), when susceptibility was established in current biopsy subjects. Non-remote 
Indigenous people have higher birth weights, though still about 100 gm short of the non-
Indigenous Australian norm, (32) and high levels of diabetes (21), while TSI people have 
largely normal birth weights (9), but very high levels of adult obesity and diabetes (9, 22).  
 
Our findings support the high frequency of glomerulomegaly previously documented in 
Aboriginal biopsies from Top End NT (19) and extend the observation to other Aborigines in 
R/VR areas, as described by subjective assessments many years ago (17). Specific 
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proliferative diseases aside, glomerular enlargement is thought to be driven by compensatory 
hypertrophy in the setting of lower nephron numbers and/or by other hypertrophic stimuli such 
as overweight or obesity, the metabolic syndrome and diabetes and perhaps inflammation 
(34).  We recently described enlarged glomeruli at autopsy in kidneys of people without 
obvious renal disease, in the presence of lower nephron number, low birth weight and obesity 
(34-39). Furthermore, in that autopsy series we found that R/VR Aboriginal people without 
renal disease had, on average, lower nephron numbers and higher glomerular volumes than 
regional non-Aboriginal controls, a difference that was probably driven by the lower birth 
weights of the Aboriginal group (40).  We have also described an association of lower birth 
weights with renal disease in the R/VR community setting (30,31).  Thus glomerulomegaly in 
biopsied R/VR Aboriginal people probably represents compensatory hypertrophy in the 
presence of congenital nephronopenia related to low birth weight and intrauterine growth 
restriction, with variable superimposition of postnatal effects of body size, metabolic disorders 
and infection/inflammation.  This is compatible with Brenner’s nephropathy of oligonephronia 
in a multi-determinant or “multihit” model of renal disease in a high risk environment (41,42). 
Obesity is a less likely to be a primary driver of glomerulomegaly in this setting, for in some 
R/VR communities rates of overweight and obesity are considerably below those for non-
Indigenous Australians (43,44). Nephron deficiency is less likely to contribute to 
glomerulomegaly and renal disease in non-remote Aboriginal people and still less in TSI 
people, who have higher birthweights, but higher rates of overweight, diabetes and the 
metabolic syndrome. 
 
The association of glomerular enlargement with FSGS demonstrated in the R/VR Aboriginal 
groups is also consistent with our previous observation in a smaller number of Top End 
Aboriginal biopsies (20).  Hughson et al have described a similar sequence with FSGS in 
biopsies of African Americans (45).  Glomerular tuft injury might be mediated through deficient 
podoctye coverage of glomerular basement membrane as glomeruli enlarge, as observed in a 
model of nephronopenia by Kriz (46), with the largest volumes, demonstrated in biopsies with 
mesangial change only, representing the earliest phase of injury, and FSGS a more advanced 
stage.  We suggest that glomerular enlargement underlies excessive susceptibility to injury in 
the presence of other predisposing factors.  Glomerulomegaly and its accompaniments will be 
further addressed in subsequent manuscripts.  
 
Excess renal disease in Indigenous Australians is commonly attributed to type 2 diabetes (2).  
However, fewer than half the Indigenous biopsy subjects were recorded as diabetic at biopsy, 
and not all their biopsies showed diabetic change. In fact, among the great excess of biopsies 
among R/VR Aboriginal people, only one quarter had definitive diabetic change. Although 
rates of diabetes are high, and many Indigenous people have acquired the diagnosis by age 
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of 45 years, such a history does not mean that diabetic nephropathy is the primary cause of 
renal disease in a given patient.  This is supported by community-based studies in R/VR 
Indigenous people that show substantial prevalence of proteinuria in people without diabetes 
(29,22,21,47), demonstrate that proteinuria/albuminuria appear at higher rates and earlier in 
life than diabetes (47,48), and predict, often by many years, the later development of diabetes 
(49).  Thus, albuminuria seems to be part of the hemodynamic/ 
metabolic/ renal syndrome, of which diabetes is a later and variable element.  We 
acknowledge, however, that most diabetic patients with a clinical picture compatible with 
diabetic nephropathy do not undergo renal biopsies to confirm a diagnosis, and concede that 
diabetes facilitates and accelerates progression of kidney disease of most causes.    
 
High levels of immune complex and post-infectious disease are compatible with the persistent 
and recurrent infections and the elevated inflammatory markers in these environments (23,50-
53).  Excessive accumulation of immune complexes and other deposits and/or their defective 
clearance could also contribute to, or result from, the mesangiopathy that accompanies 
glomerular enlargement, at least in the nephron deficiency model (46).  
 
The female excess in renal disease, seen in the RRT population, in community screening 
programs and now in biopsies in R/VR Aboriginal and TSI people, is not completely 
understood, although partial explanations might lie in the lower nephron endowment in 
females (about 17% fewer nephrons (54)), their lower birth weights, higher BMIs and greater 
central fat deposition, higher rates of diabetes until mid life, and perhaps the effects of 
pregnancy.   
 
There are many limitations to this study.  The consolidation of non-remote Aboriginal people 
into only one category, obscures potential additional differences.  Deficient Indigenous 
assignment could influence case ascertainment, as well as population denominators.  
Nephrologists’ recall is undoubtedly incomplete, and the designation of “at least half 
Indigenous” is precarious.  There are also variations in renal disease patterns and rates by 
community, region and state/territory, which were not represented in equal proportions in the 
series. Furthermore, levels of awareness and ascertainment of preterminal renal disease have 
varied by region and over time, as have availability of nephrology expertise and philosophies 
about biopsies.  For example, the first spate of biopsies in the Top End of the NT was driven 
by need to define the lesions. More recently, biopsies have often been limited to people in 
whom unusual findings might change management, beyond general renal protection and 
metabolic and blood pressure control. And, as already noted, diabetics with renal disease are 
usually not biopsied.  Nonetheless important patterns are exposed for the first time by this 
series.   
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In summary, there are differences in kidney biopsy rates and findings in Australia’s Indigenous 
people. They correlate with similar differentials in ESRD and in mortality. They might be partly 
explained by differences in stages in the epidemiological and health transitions, in 
environmental and socioeconomic circumstances, and in genotype and genetic admixture.  
Due to this variation, predictions and preventative efforts cannot be based solely on the size of 
the Indigenous population in various regions, states and territories. The greatest absolute 
reduction in numbers of Indigenous people starting RRT will be achieved through intensive 
targeting of risk factors in R/VR Aboriginal and in TSI people. Continued improvements in birth 
weight and reductions in infections promise ultimate reductions in renal disease in those 
settings, if temporal trends in increase of BMI can be contained. 
 
Methods 
 
All nephrologists in Australia were invited to participate, through identification of 
Indigenous people who had undergone kidney biopsy, and through participation in biopsy 
reviews.  The major pathology laboratories in each region were likewise requested to 
identify Indigenous renal biopsies where possible.  Ethical review boards at each clinical 
centre and laboratory, as well as the participating academic centres, and their Indigenous 
subcommittees, approved the study.   
 
The review was restricted to people considered to be at least half Indigenous.  Slides from 
contemporaneous biopsies on non-Indigenous people were also retrieved in an approximate 
ratio of one per 3 Indigenous biopsies. Demographic data were derived from hospital 
databases or biopsy referral forms. Clinical summaries were taken from biopsy referral sheets; 
the detail was sometimes very deficient.  
 
The expert review group consisted of 5 international nephropathologists (AF, JD, MH, PKS, 
RS). They, and other interested persons, met for four week-long meetings over a period of 
three years.  A data collection form (Table 2) was developed through a process of progressive 
modification as findings dictated. The panel, initially blinded to ethnicity, demographic and 
clinical history of the biopsied subjects, recorded findings on LM review of the slides, and their 
tentative assessments. The reviews were conducted either in committee, or discussed by the 
whole committee following review by individual experts. The panel later reviewed their 
assessments as photographs and reports of IF and EM studies became available. The 
presence, localization and nature of immune complex deposits were determined and GBMs 
examined. Finally, diagnoses were refined in the context of an individual’s information from all 
sources, including available clinical data.   
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In a subsequent phase, glomerular tuft and corpuscle volumes in each biopsy were estimated, 
as previously described (19), through application of the Weibel and Gomez formula to the 
average measurement of the areas of all available glomerular profiles on a given section. 
Later steps included formal measurement of glomerular sclerotic index, interstitial fibrosis and 
GBM thickness, with techniques and the findings described in later manuscripts.  
 
Statistical analyses were conducted using Stata Statistical Software: Release 11 (55). 
Summary data are presented as means with standard deviations or as category 
percentages. Means were compared using the t-test, accounting for unequal variance as 
necessary. Proportions were compared using the Chi-squared or the Fisher’s exact tests.  
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Table 1.  Indigenous Australian population, 2006, by states and territories and remoteness areas,  
                Australian Bureau of Statistics, “Place of Usual Residence” 
 
 
 
Indigenous      
population 
Population by categories of remoteness, number/% 
 
Major 
City 
Inner 
Regional 
Outer 
Regional Remote 
Very 
Remote 
New South Wales 138,057 52.9% 33.5% 18.5% 4.3% 0.8% 
Queensland Aboriginal 98,305 32.0% 22.5% 26.5% 9.9% 9.1% 
Queensland TSI 18,310 16.3% 13.3% 34.1% 1.5% 34.8% 
Western Australia 58,476 35.2% 8.2% 15.0% 15.6% 26.0% 
Northern Territory 53,492 - - 19.5% 22.9% 57.6% 
Victoria 30,055 49.2% 35.3% 15.5% 0.1% - 
South Australia 25,469 48.9% 9.2% 23.3% 4.2% 14.5% 
Tasmania 16,721 - 53.7% 42.7% 2.4% 1.3% 
Australian Capital Territory 3,850 99.8% 0.2% - - - 
Source: Adapted from Australian Bureau of Statistics. 2007 (11) 
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Table 2.   Light microscopic data collection items 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Number of glomeruli in section: 
 
 
2 Mesangial matrix expansion: 
none / mild / moderate / severe  
3 Mesangial hypercellularity: 
none / mild / moderate / severe  
4 Mesangial interposition:                                    no / yes  
5 Mesangiocapillary change:                                no / yes  
6 Glomerular deposits:                                          no / yes  
  epimembranous:                                 no / yes 
                   intramembranous:                              no / yes 
subendothelial:                                   no / yes 
         mesangium:                                        no / yes 
   capillary lumen:                                  no / yes 
7 Membranous changes:                                       no / yes  
      holes / spikes / deposits 
8 Endocapillary proliferation:                              no / yes  
      with significant PMNs (>3):              no / yes 
9 Crescents:                                                            no / yes  
                    in how many glomeruli: 
 cellular crescents:                            no / yes 
                    in how many glomeruli: 
 fibrocellular crescents:                    no / yes 
                    in how many glomeruli: 
 fibrous crescents:                             no / yes 
                    in how many glomeruli: 
10 Glomerulonecrosis:                                            no / yes  
11 Glomerular capillary thrombosis:                    no / yes  
12 Segmental glomerulosclerosis:                          no / yes  
                    in how many glomeruli: 
                    with hyalinosis:                                no / yes 
                    in hw many glomeruli: 
                   with foam cells:                                no / yes 
                    in how many glomeruli: 
13 Tip lesions:                                                          no / yes  
                    in how many glomeruli: 
 with foam cells:                                 no / yes 
14 Adhesions:                                                           no / yes  
                     in how many glomeruli: 
15 Segmental ischaemic glomerulosclerosis:         no / yes  
                     in how many glomeruli: 
16 Indeterminate segmental sclerosis:                   no / yes 
                     in how many glomeruli: 
17 Perihilar sclerosis/adhesions:                            no / yes  
                     in how many glomeruli: 
 with hyalinosis:                                 no / yes 
18 Collapsing lesion:                                                no / yes  
                     in how many glomeruli: 
19 Glomerular solidification:                                 no / yes 
                     in how many glomeruli: 
  20 Glomerular obsolescence:                                  no / yes 
                     in how many glomeruli: 
21 Global glomerulosclerosis with hyalinosis:     no / yes    
                     in how many glomeruli:   
22 Glomerular infiltration:                                    no / yes 
                     in how many glomeruli: 
23 Interstitial inflammation: 
none / mild / moderate / severe 
 lympho-histiocytic:                          no / yes 
            plasmacytic:                                      no / yes 
         granulomatous:                                 no / yes 
              eosinophils:                                       no / yes 
                     PMNs:                                              no / yes 
24 Interstitial fibrosis:     none / mild / moderate / severe 
25 Interstitial hemorrhage:                                    no / yes 
26 Periglomerular fibrosis:                                    no / yes 
                     in how many glomeruli: 
27 Fragmentation Bowman’s capsule:                  no / yes 
                     in how many glomeruli: 
28 Tubulitis:                     none / mild / moderate / severe 
                         PMNs / lymphocytes / eosinophils 
29 Tubular atrophy:        none / mild / moderate / severe 
30 Juxtaglomerular apparatus prominent:          no / yes 
31 Intimal fibrosis: interlobular arteries: 
         none / mild / moderate / severe  
32 Intimal fibrosis: arcuate arteries: 
         none / mild / moderate / severe  
33 Arteriolar hyalinosis:   
          none / mild / moderate / severe  
34 Hyalinosis of interlobular arteries: 
          none / mild / moderate / severe  
35 Fibrinoid necrosis:                                             no / yes  
                                          arterioles / interlobular arteries 
36 Arteriolar thrombosis:                                       no / yes 
37 Comment: glomerular size:       small / normal / large 
38 Comments: 
 
 
 
 
 
 
 
39 Diagnosis: 
 
 
1 
 
2 
 
3 
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Table 3.   The number of evaluable Australian Indigenous biopsies by state/territory  
                 and remoteness and ethnic group    
 
Indigenous Australians 
by State/Territory 
N 
Indigenous Australians 
by remoteness/ethnic grouping 
N 
    
   
Central Australia 210 Very Remote Aboriginal 86 
Top End Northern Territory 143 Remote Aboriginal 65 
Queensland  201 Outer Regional Aboriginal 63 
Western Australia 54 Inner Regional Aboriginal 3 
South Australia 40 Major City Aboriginal 19 
New South Wales 5 Torres Strait Islander 73 
ACT/Victoria/Tasmania 0 Torres Strait Islander/Aboriginal 12 
                   ACT: Australian Capital Territory 
 
 
 
                      
Table 4.  Characteristics of persons in the biopsy series and features of their biopsies 
 Non-Indigenous 
Aboriginal 
Non-remote* 
Torres Strait 
Islander 
Aboriginal 
Remote/Very 
Remote 
Non-
Indigenous 
vs 
Indigenous 
Aboriginal 
Remote/Very 
Remote vs 
other 
Indigenous 
 N=249 N=92 N=84 N=455 PØ PØ 
Demographic and clinical features       
Female, % 40.2 46.74 56.0 55.4 <0.001 0.337 
Age, yr , mean (SD) 45.2 (16.6) 43.3 (14.4) 45.6 (15.8) 39.2 (13.9)§ 0.0002Ø 0.0001Ø 
Known diabetes, % 14.6 48.3 42.9 42.4 <0.001 0.459 
Proteinuria±, % 67.5 77.5 71.4 85.5 <0.001 0.001 
Heavy proteinuria+, % 22.2 33.7 36.9 43.2 <0.001 0.073 
Renal insufficiency†, % 43.2 59.6 61.9 54.2 0.001 0.144 
Renal failure‡, % 16.6 32.6 33.3 22.5 0.006 0.007 
       Morphologic features       
Glomerular profiles per biopsy, 
median (IQR) 15 (10-24) 14 (9-20) 15 (8-23) 14 (8-22) 0.0405 0.5951
 Ø 
Mean glomerular volume ∑, µm3 x106,  
mean (95% confidence interval) 
2.57 (2.4-2.8) 2.54 (2.2-2.9) 2.47 (2.2-2.8) 3.78 (3.6-4.0) <0.0001 Ø <0.0001 Ø 
Mesangiopathic change, % 84.3 94.6 94.1 92.8 <0.001 0.483 
Segmental sclerosis, % 45.8 56.5 57.1 63.3 <0.001 0.134 
Crescents, % 13.4 18.7 14.8 10.9 0.741 0.046 
Percentage of glomeruli per biopsy, with 
crescents, median (IQR) 16.7 (5.3-46) 16.7 (8.3-28.0) 10.4 (8.0-33.0) 13.8 (8.7-33.3) 0.388
 Ø 0.316 Ø 
Interstitial inflammation/fibrosis, % 88.7 94.4 91.5 91.2 0.167 0.449 
Vascular change, % 72.7 81.5 82.1 79.1 0.021 0.449 
End stage kidney, % 0.4 4.4 1.2 1.5 0.125 0.330 
       
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Non-remote: Major city, inner regional and outer regional place of residence 
P: T-test/Chi-squared test, Ø T-test unequal variance option or Fisher’s Exact test, SD: Standard deviation.  IQR: Inter-quartile range 
GN: glomerulonephritis 
±Proteinuria: Albumin creatinine ratio ≥34gm/mol or protein creatinine ratio ≥50gm/mol or dipstick protein: ≥1+ or ≥0.15gm/day or ≥0.15gm/L, or stated in history 
+Heavy proteinuria: Albumin creatinine ratio ≥300gm/mol or urinary protein: dipstick ≥3+ or ≥3gm/day or ≥3gm/L, or stated in history 
†Renal impairment: S creatinine: >106µmol/L if female or >120µmol/L if male, or stated in history.  ‡Renal failure: S creatinine ≥400µmol/L or stated in history 
∑End-stage kidneys excluded 
××Additionally: there were 5 cases of reflux nephropathy in remote/very remote Aboriginal (1.1%), as well as rare cases of light chain disease 3 (0.7%), Henoch-Schönlein 
purpura 0, pyelonephritis 6 (01.3%), thrombotic thrombocytopenic purpura 3 (0.7%) and vasculitis 1 (0.2%), arteriolar nephrosclerosis 20 (4.4%) acute tubular necrosis 1 (0.2%) 
ΩMesangiopathic GN, with or without immune complexes but excluding IgA nephropathy or focal segmental glomerulosclerosis,  
ѳTwo or more assessments/diagnoses.  Note: secondary focal segmental glomerulosclerosis not counted as a separate diagnosis.   
#Two or more diagnoses: Major groups: Diabetic nephropathy and post-infectious GN, diabetic nephropathy and IgA nephropathy, diabetic nephropathy and interstitial 
nephritis, diabetic nephropathy and diffuse proliferative GN 
§R/VR Aboriginals were significantly younger than all others biopsied, p<0.0001 
Assessments/diagnoses××       
Diabetic nephropathy, % 8.4 41.3 48.8 26.6 <0.001 <0.001 
Focal segmental glomerulosclerosis, % 16.1 12.0 9.5 19.6 0.707 0.009 
Mesangiopathic GNΩ, % 13.7 6.5 6.0 14.2 0.769 <0.001 
IgA nephropathy, % 24.4 19.1 18.2 12.7 0.001 0.067 
Diffuse proliferative GN 9.6 12.0 8.3 5.9 0.213 0.060 
Post-infectious GN, % 1.6 8.7 11.9 5.9 0.001 Ø 0.060 
Interstitial nephritis, % 9.2 4.4 2.4 4.4 0.003 0.576 
Membranoproliferative GN, % 3.6 3.3 3.6 4.0 0.894 0.747 
Amyloidosis, % 0.8 0.0 0.0 3.7 0.120 Ø 0.005 Ø 
Lupus nephritis, % 6.4 5.4 2.4 3.7 0.093 0.887 
Hypertensive renal disease, %  4.0 6.5 6.0 2.9 0.883 0.046 
Minor change only, %  4.4 0 2.4 2.0 0.022 0.469 
Membranous GN , % 6.8 5.4 1.2 1.5 <0.001 0.138 
Two or more diagnosesѳ, % 5.6 12.0 20.2 9.7 0.009 0.027 
Two or more diagnosesѳ, major groups#, % 1.2 7.6 13.1 7.0 <0.001 0.183 
                      
Table 5.   Diabetic nephropathy classification in the biopsy series (26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Non-remote: Major city, inner regional and outer regional place of residence 
LM: Light microscopy, EM: Electron microscopy, GBM: Glomerular basement membrane 
 
 
 Diabetic nephropathy classification Non-Indigenous 
Aboriginal 
Non-remote* 
Torres Strait 
Islander 
Aboriginal 
Remote/Very 
Remote 
Class  N=21 N=38 N=41 N=121 
I 
Mild or non-specific LM changes  
and EM-proven GBM thickening 
1 (4.8%) 0 0 0 
IIA Mild mesangial expansion 2 (9.5%) 2 (5.3%) 5 (12.2%) 15 (12.4%) 
IIB Severe mesangial expansion 9 (42.9%) 13 (34.2%) 14 (34.2%) 58 (47.9%) 
III Nodular sclerosis (Kimmelstiel-Wilson lesion) 4 (19.1%) 7 (18.4%) 6 (14.6%) 14 (11.6%) 
IV Advanced diabetic glomerular sclerosis 5 (23.8%) 16 (42.1%) 16 (39.0%) 34 (28.1%) 
                      
Table 6.   Classification of focal segmental glomerular sclerosis in the biopsy 
series  
 
 
 
FSGS: Focal segmental glomerulosclerosis 
*Non-remote: Major city, inner regional and outer regional place of residence 
+The Columbia classification (27)) 
An assignment of Secondary FSGS was given if any of the following clinical-pathologic conditions were 
present; diabetes mellitus, diabetic nephropathy, IgA nephropathy, lupus nephritis, thin membrane 
nephropathy, immune complex glomerulonephritis, pyelonephritis, reflux nephropathy, familial nephritis or 
morbid obesity. The remaining biopsies were assigned as Primary FSGS. 
Classification and class Non-Indigenous 
Aboriginal 
Non-remote* 
Torres Strait 
Islander 
Aboriginal 
Remote/Very 
Remote 
Aetiologic     
          Primary FSGS 17 (6.8%) 5 (5.4%) 2 (2.4%) 29 (6.4%) 
          Secondary FSGS 23 (9.2%) 6 (6.5%) 6 (7.1%) 60 (13.2%) 
     Histologic+     
 Primary FSGS 
 
N=17 N=5 N=2 N=29 
    Not otherwise specified 
 
14 (82.4%) 5 (100.0%) 2 (100.0%) 15 (51.7%) 
    Perihilar variant 
 
2 (11.8%) 0 0 12 (41.4%) 
    Tip variant 
 
1 (5.9%) 0 0 0 
    Collapsing variant 
 
0 0 0 1 (3.5%) 
    Cellular variant 0 0 0 1 (3.5%) 
       Secondary FSGS  N=23 N=6 N=6 N=60 
    Not otherwise specified 
 
 
 
 
13 (56.52%) 5 (83.3%) 4 (66.7%) 38 (63.3%) 
    Perihilar variant 
 
9 (39.1%) 1 (16.7%) 2 (33.3%) 18 (30.0%) 
    Tip variant 
 
0 0 0 1 (1.7%) 
    Collapsing variant 
 
0 0 0 1 (1.7%) 
    Cellular variant 1 (4.35%) 0 0 2 (3.3%) 
                      
Table 7.   Clinical correlates of focal segmental glomerular sclerosis (FSGS) in the 
biopsy series 
 
 
±Proteinuria: Albumin creatinine ratio ≥34gm/mol or protein creatinine ratio ≥50gm/mol or dipstick protein ≥1+ 
or ≥0.15gm/day or ≥0.15gm/L, or stated in history 
+Heavy proteinuria: Albumin creatinine ratio ≥300gm/mol or urinary protein: dipstick ≥3+ or ≥3gm/day or 
≥3gm/L, or stated in history 
†Renal impairment: S creatinine: >106µmol/L if female or >120µmol/L if male, or stated in history; ‡Renal 
failure: S creatinine ≥400µmol/L or stated in history 
P: Chi-squared test, Ø Fisher’s Exact test, IQR: Inter-quartile range  
 
 
 
 
 
 
 
 
 
 
Correlate, % 
Non-
Indigenous 
Aboriginal 
Non-remote* 
Torres Strait 
Islander 
Aboriginal 
Remote/Very 
Remote 
Non-
Indigenous 
vs 
Indigenous 
Aboriginal 
Remote/Very 
Remote 
Vs 
other 
Indigenous 
Primary FSGS N=17 N=5 N=2 N=29   
Proteinuria± 60.0 60.0 100.0 89.7     0.061Ø     0.244Ø 
Heavy proteinuria+ 40.0 20.0 100.0 51.7     0.554 Ø     1.00 Ø 
Renal impairment† 46.7 60.0 50.0 44.8     0.971     0.684 Ø 
Renal failure‡ 20.0 0 0 3.5     0.071 Ø     1.00 Ø 
       Secondary FSGS  N=23 N=6 N=6 N=60   
Proteinuria± 59.1 83.3 83.3 93.3     0.002Ø     0.260Ø 
Heavy proteinuria+ 22.7 33.3 0 45.0     0.204Ø     0.106 Ø 
Renal impairment† 31.8 66.7 16.7 40.0     0.475     1.00 Ø 
Renal failure‡ 4.6 33.3 0 13.3     0.448Ø     0.669 Ø 
                      
Fig 1. Australian Bureau of Statistics’ Accessibility/Remoteness Index of Australia 
(ARIA+)  
Source: Australian Bureau of Statistics, 2006 (10) 
 
 
 
 
                      
Figure 2. Standardised incidence rates of ESRD resulting in RRT in Indigenous 
Australians in selected regions, 1993-1998 
Note: Standardized incidence ratio  
Index population for standardization was the total Australian resident population.  
Source: Adapted with permission, Cass et al., 2001(12) 
 
 
 
 
 
                      
Figure 3. Two year rolling average of annual incidence of ESRD treated by RRT in  
                Indigenous Australians, by state/territory 
Notes: 
ESRD: End-stage renal disease 
RRT: Renal replacement therapy 
NSW: New South Wales 
ACT: Australian Capital Territory 
Source: Adapted from McDonald et al., 2010 (2) 
 
 
 
 
 
 
 
 
 
 
 
 
  
                      
Figure 4.  
4a. Biopsy frequency per million persons 
4b. Average annual RRT incidence per million persons, 2005-2008 
4c. Prevalence of overt albuminuria from community or regional surveys in Australian 
Indigenous groups 
 
Notes: 
RRT: Renal replacement therapy 
TSI: Torres Strait Islander 
R/VR: Remote or very remote living 
Sources: 
4a. Denominator: Australian Bureau of Statistics, 2007 (11) 
4b. ANZDATA, August 2011 (personal communication) and Australian Bureau of Statistics, 2007 (11) 
4c. Darwin: Maple-Brown et al., 2011 (21), TSI: Leonard et al., 2002 (22), Aboriginal R/VR: Derived, using 
average rates from McDonald et al., 2003 (23) and Rowley et al., (24) 
                      
Figure 5. Mean glomerular volume in biopsies of non end-stage kidneys among study 
groups 
Note: 
R/VR: Remote or very remote living 
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Figure 6. Mean glomerular volume in biopsies of non end-stage kidneys in remote/very 
remote Aboriginal people by mutually exclusive diagnostic categories 
Notes:  
FSGS: Focal segmental glomerulosclerosis 
GN: Glomerulonephritis 
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Figure 7. Estimated relative frequency of biopsy assessments per million population 
Notes: 
TSI: Torres Strait Islander 
R/VR: Remote or very remote living 
GN: Glomerulonephritis 
FSGS: Focal segmental glomerulosclerosis 
Source: Denominator, Australian Bureau of Statistics. 2007 (11) 
 
